On May 28, 2026, Eli Lilly and Company announced it will present new data on retatrutide — along with data on Mounjaro (tirzepatide) and Foundayo (oral GLP-1) — at the American Diabetes Association's 86th Scientific Sessions. The announcement framed the presentation as part of a broader effort toward what Lilly described as "a new era of choice in diabetes and obesity care." For the many patients and clinicians closely watching retatrutide's development, this presentation represents one of the most significant public data events to date for a drug that has already broken records in Phase 3 testing.
Retatrutide — commonly referred to as reta in patient communities — is a triple agonist targeting the GLP-1, GIP, and glucagon receptors simultaneously. This tri-receptor mechanism, sometimes called triple G in online obesity communities, distinguishes retatrutide from all currently approved obesity medications. The glucagon receptor component, absent in both semaglutide and tirzepatide, is thought to drive additional energy expenditure, which may help explain reta's unprecedented efficacy signals.
According to Lilly's May 28, 2026 press release, the ADA presentation will include new analyses from the ATTAIN program — retatrutide's Phase 3 clinical trial program. This is notable because peer-reviewed Phase 3 publication remains pending as of April 2026, meaning the ADA Scientific Sessions may represent one of the first formal scientific forums where detailed ATTAIN data is presented to the medical community.
The context here matters enormously. In December 2025, Lilly announced top-line results from TRIUMPH-4, one of the Phase 3 trials within the ATTAIN program. That trial — 68 weeks in duration — reported a mean weight loss of 28.7% at the 12mg dose, the highest mean weight loss ever recorded in a Phase 3 obesity trial. To put that in perspective: participants at the highest dose lost more than one-quarter of their total body weight on average. Many patients following this drug have been waiting for those results to be formally contextualized, analyzed, and presented in a peer-reviewed scientific setting. The ADA sessions appear to be the next step in that process.
Beyond total weight loss, earlier Phase 2 data published in the New England Journal of Medicine in 2023 showed that at 48 weeks, 64% of participants on 12mg lost at least 20% of body weight, and 48% lost at least 25%. Cardiometabolic markers also improved substantially — fasting triglycerides fell by 34% at 12mg at week 24, and total cholesterol dropped by 17.3%. Quality of life scores, measured by SF-36v2, improved across all active dose groups. The ADA presentation of new ATTAIN analyses is expected to expand on what the Phase 2 data only hinted at.
Lilly's ADA presence extends beyond retatrutide. The same announcement confirmed that Phase 3 ACHIEVE trial results for Foundayo, Lilly's oral GLP-1 receptor agonist, will also be presented. This oral formulation expands accessibility for patients who are needle-averse or who may transition from injectable therapy. Data on Mounjaro (tirzepatide) will also be featured, underscoring Lilly's growing portfolio in cardiometabolic medicine.
Together, these presentations reflect a company positioning itself across the full spectrum of weight management and diabetes care — from oral daily GLP-1s to injectable dual agonists to, potentially, the most effective injectable obesity treatment ever brought to Phase 3 testing. For patients navigating obesity treatment options, this breadth of data at a single scientific meeting is historically unusual and clinically meaningful.
The table below places retatrutide's Phase 3 efficacy in context alongside the landmark Phase 3 trials for the two currently approved injectable obesity medications:
| Drug | Mechanism | Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg (Zepbound) | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-4 (Phase 3) | 68 weeks | 28.7% |
It is worth noting that retatrutide is not yet FDA-approved, and the NDA has not been filed as of April 2026. The TRIUMPH-4 figures above are sourced from a Lilly press release; peer-reviewed Phase 3 publication is pending. Nonetheless, the trajectory from Phase 2 to Phase 3 has been remarkably consistent — and the ADA presentation of new ATTAIN analyses will be closely scrutinized by the clinical community.
Scientific presentations at major meetings like the ADA's Scientific Sessions often precede or coincide with regulatory milestones — data disclosure, NDA filings, or advisory committee meetings. While no NDA filing date or FDA approval timeline for retatrutide has been publicly confirmed as of April 2026, the presentation of new ATTAIN program analyses at ADA 2026 signals that the regulatory package is maturing.
Patients following reta's development should understand that ADA presentations are a critical step in scientific validation. When peer-reviewed data is formally presented and discussed by endocrinologists, cardiologists, and obesity medicine specialists, it creates the evidentiary foundation that supports an NDA submission and eventual FDA review. The May 2026 announcement explicitly invokes a "new era of choice" in obesity care — language that suggests Lilly views these presentations as part of a broader commercial and regulatory readiness narrative.
There are also important safety considerations receiving attention. In TRIUMPH-4, dysesthesia — an abnormal or unpleasant skin sensation — occurred in 20.9% of participants at the 12mg dose, compared to 0.7% in the placebo group. Discontinuation rates were 18.2% at 12mg versus 4.0% for placebo, with some discontinuations attributed to what was described as perceived excessive weight loss. These are not trivial findings, and the ADA presentation of detailed ATTAIN analyses will be an opportunity for the medical community to evaluate the full benefit-risk profile of retatrutide in a rigorous scientific context. Notably, some patients experience meaningful weight reduction — and significant reduction in food noise — at doses below 12mg, which may carry a more favorable tolerability profile for certain individuals.
For patients living with obesity, the convergence of Phase 3 data, peer-reviewed presentations, and Lilly's pipeline disclosures at ADA 2026 represents a moment of genuine clinical momentum. The science appears to be moving quickly, and the medical community is paying close attention.
If retatrutide is a treatment option you want to stay informed about, glp3md.com maintains a dedicated waitlist and information platform for individuals following reta's development. Joining the waitlist keeps you informed as new data, regulatory developments, and availability updates emerge. Please note: joining the waitlist makes no promises about access to medication, treatment, or prescriptions. Retatrutide is not FDA-approved, and the waitlist is for informational purposes only. Visit glp3md.com to add your name and stay ahead of the latest developments in what may become the most consequential advance in obesity medicine in a generation.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.